HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
Nalini Kumari, Speaker at Obesity Conference
Apollo Sugar Clinics, India


Background: The prevalence of overweight and obesity in India is rapidly increasing than the world’s average. For instance, between 1998 and 2015, the prevalence of overweight among women increased from 8.4% to 15.5%, and obesity increased from 2.2% to 5.1% The increasing prevalence of obesity is a growing concern for many chronic diseases.

Methods: Apollo Sugar is a pan India network of Diabetes and Endocrinology Clinics with more than 45,000 registered patients. Data of 6439 patients were available during the duration of study period (i.e., from March 2020 to March 2021), and a complete data set was available for 2458 patients from the Electronics Medical Records (EMR). 

Among the Type 2 DM patients, over 20 years of age who attended the OPD, and were overweight as well as obese were identified on the basis on the Body Mass Index (BMI) criteria prescribed by the WHO.
Patients with Type 1 DM, Gestational Diabetes Mellitus (GDM), Thyroid Disease, Diabetes with Thyroid disease, Cushing Syndrome, Acute Myocardial Infarction (MI), Acute Heart Failure (HF), Acute Kidney Disease (AKD), Chronic Kidney Disease (CKD) were excluded from the study. A cross-sectional analysis was done.

Results:  The overall prevalence of overweight and obesity was 39.47%, with male 58.08% (n=1471), and female 42.34% (n=1077). The prevalence of overweight and obesity in male patients was maximum in the age group of 51-60 years was 27.97% (n =414). The prevalence among different BMI categories were as follows: in Overweight category was 68.73% (n =1011), Class I Obesity was 23.66% (n =348), Class II Obesity was 5.85% (n = 86), and Class III Obesity was 1.78% (n= 26).

The prevalence of overweight and obesity in female patients was maximum in the age group of (51-60) years was 33.64% (n = 363). The prevalence with respect to BMI categories were: in Overweight was 54.87 % (n =591), Class I Obesity was 30.83% (n=332), Class II Obesity was 10.77% (n =116), Class III Obesity was 3.53% (n=38).The prevalence of overweight and obesity in younger age group of (20-40) years was 18.96% (n=483), and in elderly group >60 years was 28.96 % (n=738). The percentage of morbid obesity was 2.5 % (n=64).

Conclusion: The overall prevalence of overweight and obesity was more in male patients and rising obesity is a growing concern for many chronic diseases. Young population will suffer comorbidity for longer period


Dr. Nalini Kumari’s career spans over 11 years in medicine, consulting, and pharma research. She brings her comprehensive knowledge to accelerate the clinical development process by designing and implementing innovative, adaptive, platform trials and clinical studies across all therapeutic areas. Currently, she is working at Apollo Sugar Clinics as Senior Manager, Medical Affairs & Research, where she is responsible for conducting scientific studies for various therapeutics areas and medical products. In this role, she also oversees clinical partnerships, strategic CRO relationship.

Before this, Dr. Nalini served as a Head of Clinical Pharmacology and Principal Investigator at rapidly growing ZenRise CRO at Hyderabad. Here she partnered with various global pharma companies for their Phase-II, III, and Phase-IV trials, also did clinical research/ pharma consulting services. She has also worked with Sipra Labs as Principal Investigator and Site Monitor and has led numerous research studies and projects. In the past, Dr.Nalini has worked in various government and private hospitals (namely, E.S.I. Hospital - Nagpur, Jharkhand Govt. P.H.C. – Jamshedpur, Apollo Hospital – Hyderabad, etc.) as Medical Officer and Consulting Physician.

Dr. Nalini has obtained M.D. (Pharmacology) degree from Government Medical College (GMC), Nagpur, one of the premier medical institutions of India. She did her M.B.B.S. from Rajendra Institute of Medical Science (RIMS), Ranchi. She has experience driving initiatives that impact global processes, people, and technology, which creates value for external partners and the company.